A comprehensive investigation was carried out by Junnan Wu and colleagues involving 3565 incident PD patients from five PD centres, encompassing the period from January 1, 2005, to May 31, 2020. Prior to the commencement of PD, baseline variables were recorded within a week. By utilizing cause-specific hazard models, the relationship between total cholesterol levels and mortality was thoroughly explored.
The findings of the study were:
● During the follow-up period, a total of 820 patients (23.0%) experienced mortality, with 415 of them being cardiovascular deaths.
● Analysis of restricted spline plots revealed a U-shaped relationship between total cholesterol levels and mortality.
● Comparing the results to the reference range (4.10–4.50 mmol/L), elevated total cholesterol levels (> 4.50 mmol/L) were associated with increased risks of both all-cause mortality (hazard ratio [HR] 1.35, 95% confidence index [CI] 1.08–1.67) and cardiovascular mortality (HR 1.38, 95% CI 1.09–1.87).
● Lower total cholesterol levels (< 4.10 mmol/L) compared to the reference range were also linked to higher risks of all-cause mortality (HR 1.62, 95% CI 1.31-1.95) and cardiovascular mortality (HR 1.72, 95% CI 1.27–2.34).
This U-shaped association challenges the conventional belief that high cholesterol levels are universally detrimental to health. It highlights the importance of considering individual patient characteristics and tailoring treatment approaches accordingly. Further research is needed to understand the underlying mechanisms driving this association and to validate the findings in larger and more diverse patient populations.
The implications of these findings are significant for the management of PD patients. Healthcare professionals should consider the total cholesterol levels within the optimal range as a potential indicator of better health outcomes and lower mortality risk. However, it is crucial to approach cholesterol management holistically, taking into account other factors such as comorbidities and individual patient needs.
These unexpected results call for a paradigm shift in our understanding of cholesterol's role in PD patient care. By recognizing the existence of an optimal range for total cholesterol levels, healthcare providers can refine their treatment strategies and potentially improve patient outcomes. Future studies and clinical guidelines should take into account these findings to ensure that PD patients receive the most appropriate and effective care tailored to their specific cholesterol needs.
Reference:
Wu, J., Yang, R., Wang, X., Zhan, X., Wen, Y., Feng, X., Wang, N., Peng, F., Jian, G., & Wu, X. (2023). Total cholesterol and mortality in peritoneal dialysis: a retrospective cohort study. BMC Nephrology, 24(1). https://doi.org/10.1186/s12882-023-03187-1.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd